Xoma Royalty Corporation · NASDAQ:XOMA
Xoma Royalty — XOMA — Cowen & Company 37th Annual Health Care Conference 2017
21 slides from Xoma Royalty's conference presentation, Mar 6, 2017
Slide 1: Cowen & Company 37th Annual Health Care Conference
Cowen & Company 37th Annual Health Care Conference (Nasdaq: XOMA) March 7, 2017 Exhibit 99.1
Slide 2: Cowen & Company 37th Annual Health Care Conference
Cowen & Company 37th Annual Health Care Conference (Nasdaq: XOMA) March 7, 2017
Slide 3: Forward-looking Statements
Forward-looking Statements Certain statements in this presentation are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements regarding: future monetization opportunities, active transact
Slide 4: New Focus: What has Changed?
New Focus: What has Changed? New leadership – Jim Neal, CEO Balance sheet re-capped and scrubbed $25 Million BVF Partners investment $10 Million debt eliminated Dramatically reduced cost structure Operating cash burn cut by over 50% Further savings upon X358 licensing Headcount slashed from 180 to <
Slide 5: Investment Thesis: Drive Shareholder Value with Partner-Funded Programs
Investment Thesis: Drive Shareholder Value by Combining Revenue from a Portfolio of Partner-Funded Programs with a Lean Cost Structure Extensive portfolio of License Agreements fully funded by partners driving milestones and royalties Over $50M in potential milestones in next 36 months Multiple shot
Slide 6: Pipeline of Fully Funded Licensed Programs
Pipeline of Fully Funded Licensed Programs Realized Milestone Future Milestone
Slide 7: Diverse Portfolio Across Therapeutic Areas
Diverse Portfolio Across Therapeutic Areas ONCOLOGY CNS INFLAMMATION METABOLIC DISEASE BLOOD DISORDERS CARDIOLOGY ANTI-MICROBIAL ANTI-VIRAL
Slide 8: Example Value-Added Partnerships
Example Value-Added Partnerships Novartis anti-CD40 Antibody (CFZ533) Multiple ongoing clinical studies Milestones; tiered high-single to lower mid-teen digit royalties Novartis TGFβ Antibody Program $480M potential milestones; tiered mid-single to low-double digit royalties IND filed Novo Nordisk X
Slide 9: XOMA's Product Pipeline: Ready for Partnering
XOMA’s Product Pipeline: Ready for Partnering XOMA 358 (INSR mAb) Hypoglycemia XOMA 129 (INSR Fab) Fast onset, shorter duration reversal of insulin action XOMA 213 (Prolactin receptor) Various hyperprolactinemias Our plan is to license programs to optimize value and speed access to patients Anti-IL-
Slide 10: Hyperinsulinemia
Hyperinsulinemia High levels of insulin due to abnormal pancreatic beta cell secretion or abnormal response to glucose Causes fainting, seizure, permanent brain damage, death CONGENITAL ACQUIRED Congenital hyperinsulinism (CHI) Insulinoma Transitional neonatal hyperinsulinism Post-bariatric surgery
Slide 11: In CHI Patients, Reduced the Duration of Hypoglycemia by 25% - 70%
In CHI Patients, 358 Reduced the Duration of Hypoglycemia by 25% - 70% 9/14 CHI patients monitored with 24hr CGM with baseline hypoglycemia <70 mg/dL for >120 min Post-358 change in hypoglycemia duration Days 2,4,6 vs Non-challenge Baseline Days -2 & -1 * Excluded from analysis as they did not meet
Slide 12: In PBS Patients, Significantly Improved Glucose Control after Meal-Challenge
In PBS Patients, 358 Significantly Improved Glucose Control after Meal-Challenge Duration of Meal Tolerance and Magnitude of Improvement Increased with Increasing Dose Mean + SEM
Slide 13: Proof-of-Concept achieved with XOMA 358
Proof-of-Concept achieved with 358 - Asset is ready for Advancement or Licensure Demonstrated clinically meaningful improvement in glucose levels: Improved AM fasting glucose levels Reduced daily periods of hypoglycemia Improved time to hypoglycemia in meal tests in PBS Correction of nighttime hypog
Slide 14: XOMA 129: Potential Fast-Acting Treatment for Acute Severe Hypoglycemia
XOMA 129: Potential Fast-Acting Treatment for Acute Severe Hypoglycemia Highly potent Fab fragment of 358 which down regulates the INSR Offers potential for rapid onset, improved efficacy, and tailored duration of therapy Potential treatment for acute severe hypoglycemia 1. Frier, B. M., G. Schernth
Slide 15: XOMA for Prolactinemia: Clinical Proof-of-Mechanism Study is Underway
XOMA 213 for Prolactinemia: Clinical Proof-of-Mechanism Study is Underway 213 is a fully human, monoclonal antibody against the prolactin receptor Open IND transferred to XOMA from Novartis Significant number of patients treated for potential oncology indications for up to 48 weeks; doses up to 20x
Slide 16: Other Assets Available for Licensure
Other Assets Available for Licensure PROGRAM DEVELOPMENT STAGE INDICATION Anti-IL-2 Preclinical Immuno-oncology PTH1R Preclinical Hypercalcemia Endocrine & Oncology Indications Gevokizumab (IL-1 beta) Phase 2/3 Multiple Inflammatory Conditions
Slide 17: Antibody Libraries Available for Licensing
Antibody Libraries Available for Licensing 3 large and diverse phage libraries from normal human tissue Single-chain, Fab 100 Billion antibodies constructed from DNA sequences amplified from ~30 donors’ B-cells Include software support, proprietary vectors & chaperones Test-proven Multiple companies
Slide 18: Financial Highlights
Financial Highlights Mlddddddislddéé EQUITY ==] FINAN C IN G SHARES OUTSTANDING __ ~12.5M MILESTONES FROM FULLY EXISTING PROGRAMS BASIC DILUTED LEAN EXPENSE STRUCTURE XOMA \ 18
Slide 19: 2017 Business Objectives
2017 Business Objectives Out-license proprietary programs As appropriate to maximize value Complete restructuring initiatives to achieve “end state” expense structure Increase universe of phage licensees Expand build portfolio of fully funded programs Strengthen financial position by reducing debt
Slide 20: Investment Thesis: Drive Shareholder Value with Partner-Funded Programs
Investment Thesis: Drive Shareholder Value by Combining Revenue from a Portfolio of Partner-Funded Programs with a Lean Cost Structure Extensive portfolio of License Agreements fully funded by partners driving milestones and royalties Over $50M in potential milestones in next 36 months Multiple shot
Slide 21: Cowen & Company 37th Annual Health Care Conference
Cowen & Company 37th Annual Health Care Conference (Nasdaq: XOMA) March 7, 2017
XOMA — Cowen & Company 37th Annual Health Care Conference 2017 on 6ix